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ABSTRACT 1 
 2 
Full length endogenous feline leukemia virus (FeLV) proviruses exist within the 3 
genomes of many breeds of domestic cat raising the possibility that they may also 4 
exist in a transmissible exogenous form. Such viruses would share receptor usage 5 
with the recombinant FeLV-B subgroup, a viral subgroup that arises in vivo by 6 
recombination between exogenous subgroup A virus (FeLV-A) and endogenous FeLV. 7 
Accordingly, all isolates of FeLV-B made to date have contained a “helper” FeLV-A, 8 
consistent with their recombinatorial origin.  In order to assess whether endogenous 9 
viruses are transmitted between cats, we examined primary isolates of FeLV for 10 
which the viral subgroup had been determined for the presence of a subgroup B 11 
virus that lacked an FeLV-A. Here we describe the identification of two primary field 12 
isolates of FeLV (2518 and 4314) that appeared to contain subgroup B virus only by 13 
classical interference assays, raising the possibility of between-host transmission of 14 
endogenous FeLV. Sequencing of the env gene and U3 region of the 3’ long terminal 15 
repeat (LTR) confirmed that both viral genomes contained endogenous viral env 16 
genes. However the viral 3’ LTRs appeared exogenous in origin with a putative 3’ 17 
recombination breakpoint residing at the 3’ end of the env gene. Further, the FeLV-18 
2518 virions also co-packaged a truncated FeLV-A genome containing a defective 19 
env gene, termed FeLV-2518(A) while no helper subgroup A viral genome was 20 
detected in virions of FeLV-4314. The acquisition of an exogenous LTR by the 21 
endogenous FeLV in 4314 may have allowed a recombinant FeLV variant to outgrow 22 
an exogenous FeLV-A virus that was presumably present during first infection. Given 23 
time, a similar evolution may also occur within the 2518 isolate. The data suggest 24 
 3 
that endogenous FeLVs may be mobilised by acquisition of exogenous LTRs yielding 1 
novel viruses that type biologically as FeLV-B. 2 
 3 
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1.  INTRODUCTION 1 
 2 
Feline Leukemia Virus (FeLV) is a major pathogen of cats that causes a range of 3 
diseases, including immunosuppression and both proliferative and non-proliferative 4 
haematopoietic disorders. The four subgroups (FeLV-A, -B, -C and –T) are 5 
distinguished by their receptor usage as well as their accompanying disease 6 
manifestations. Receptor usage is determined by the Receptor-Binding Domain 7 
(RBD), located within the surface unit of the envelope glycoprotein (Env) (Bae et al., 8 
1997; Rigby et al., 1992). The prototype FeLV-A subgroup utilises a thiamine 9 
transporter protein (feThTr1) for cell entry (Mendoza et al., 2006) whilst FeLV-B 10 
utilises an inorganic phosphate-sodium symporter (fePit1) (Rudra-Ganguly et al., 11 
1998; Takeuchi et al., 1992) and displays a broader in vitro host range (Jarrett et 12 
al., 1969; Jarrett et al., 1973). Some FeLV-B isolates are also able to utilise the 13 
homologous protein fePit2 (Anderson et al., 2001; Boomer et al., 1997). 14 
 15 
Endogenous retroviruses (ERVs) arise after a proviral integration event occurs within 16 
a germline cell or during early embryogenesis. The resultant provirus is therefore 17 
maintained at this locus in every cell of the adult host. “Ancient” ERVs are therefore 18 
fixed Mendelian elements within the genome of the species, whereas more recently 19 
integrated ERVs may display polymorphisms between individuals. There are 20 
numerous FeLV-related endogenous elements (enFeLV) within the domestic cat 21 
genome (Benveniste and Todaro, 1975; Koshy et al., 1980; Okabe et al., 1976; Soe 22 
et al., 1983), most of which are polymorphic (Koshy et al., 1980; Roca et al., 2005) 23 
and have intact long terminal repeats (LTRs) (Soe et al., 1983; Soe et al., 1985). As 24 
 5 
the U3 region of the LTRs differs significantly between endogenous and exogenous 1 
FeLV genomes (Berry et al., 1988; Casey et al., 1981; Okabe et al., 1978), this 2 
domain is often analysed to determine the origin of FeLV strains (Tandon et al., 3 
2008). As enFeLV elements are generally mutated and nonfunctional, they do not 4 
form infectious virions (Soe et al., 1985), although expression of short transcripts 5 
has been observed (Busch et al., 1983; McDougall et al., 1994; Niman et al., 1980). 6 
 7 
FeLV-B arises through recombination events between the env genes of FeLV-A and 8 
enFeLV transcripts (Neil et al., 1991; Overbaugh et al., 1988; Stewart et al., 1986). 9 
Thus FeLV-B is always found alongside FeLV-A, which is generally regarded as the 10 
“helper” virus required for FeLV-B transmission (Jarrett and Russell, 1978; Sarma 11 
and Log, 1973). The recombination event leading to FeLV-B formation is 12 
hypothesised to take place within a virion that has co-packaged two distinct FeLV 13 
transcripts, however to date this has not been observed directly. The specific enFeLV 14 
loci that contribute to FeLV-B formation have not been elucidated. 15 
 16 
Recently, full length enFeLV elements with putative functional open reading frames 17 
(ORFs) have been characterized (GenBank Accession numbers AY364318 and 18 
AY364319) (Roca et al., 2004). These endogenous elements possess identical 5’ 19 
and 3’ LTRs and are present in only 9 - 15% of domestic cats (Roca et al., 2005) 20 
indicating they are relatively recent additions to the feline genome. We hypothesised 21 
that if transcription and packaging of these full-length enFeLV genomes occurred in 22 
vivo, then they may be transmitted between cats. As the RBD of FeLV-B is encoded 23 
by an enFeLV region of the recombinant genome, such infections would present as 24 
 6 
subgroup B only by interference. Interference assays, a method of classifying viruses 1 
according to their receptor usage, rely upon the fact that infection with a retrovirus 2 
leads to down-regulation of receptor expression upon the cell surface, preventing re-3 
infection by a virus of the same interference group. 4 
 5 
We examined a group of FeLV field isolates for variants that displayed the FeLV-B 6 
phenotype alone. We identified two isolates from the sera of naturally infected cats, 7 
and sequenced both the env gene and U3 motif of the viral genomes to identify their 8 
proviral origin. Although we found evidence for recombination between endogenous 9 
and exogenous transcripts, our results indicate that enFeLV may contribute more 10 
highly to FeLV transmission and pathogenesis than previously suspected. We predict 11 
that these ostensibly-FeLV-B isolates may be transmitted between hosts without the 12 
presence of FeLV-A. 13 
 14 
2.  MATERIALS AND METHODS 15 
 16 
2.1. Cell Lines 17 
 18 
Mus dunni tail fibroblast (MDTF) cells (ATCC Catalogue CRL-2017) were maintained 19 
in low-glucose DMEM, supplemented with 10% Foetal Bovine Serum (FBS), 20 
100U/mL penicillin and 100µg/mL streptomycin. Human embryo kidney (HEK293T) 21 
cells (Graham et al., 1977) were maintained in high-glucose DMEM, supplemented 22 
with 10% FBS, 100U/mL penicillin and 100µg/mL streptomycin. Feline embryo A 23 
 7 
(FEA) cells (Jarrett et al., 1973) were maintained in high-glucose DMEM, 1 
supplemented with 10% FBS, 100U/mL penicillin, 100µg/mL streptomycin, 2mM L-2 
Glutamine and 2mM sodium pyruvate. All cells were washed with phosphate-3 
buffered saline and subcultured upon confluency using Trypsin-EDTA. All media and 4 
supplements were obtained from InVitrogen Life Technologies Ltd (Paisley, U.K). 5 
 6 
MDTF cells stably expressing the human orthologue of the FeLV-C Receptor 7 
(hFLVCR1) and the feline thiamine transporter protein (feThTr1) were developed as 8 
follows: Viral particles packaging the retroviral receptor expression constructs and 9 
pseudotyped with the VSV-G envelope protein (Yee et al., 1994) were produced by 10 
transient transfection of HEK293T cells using SuperFect activated dendrimer 11 
(QIAgen Ltd, Crawley, U.K.). MDTF cells were transduced with filtered viral particles 12 
harvested 72 hours post-transfection. Stably-transduced cells were selected in the 13 
presence of 0.8mg/mL Geneticin (InVitrogen) for three weeks. Expression of 14 
retroviral receptors was confirmed by immunoblotting  (data not shown). 15 
 16 
2.2. Receptor Usage Assays  17 
 18 
The receptor usage of numerous FeLV isolates from the sera of naturally infected 19 
cats was determined using a FeLV receptor interference assay as previously 20 
described (Jarrett et al., 1973). These results were then confirmed by transfection of 21 
infected FEA cells with a construct containing the β-galactosidase gene and a 22 
Murine Leukemia Virus (MLV) packaging signal, pMFG-lacZ (Ohashi et al., 1992). 23 
 8 
Pseudotypes were harvested 72 hours post-transfection and used to infect MDTF 1 
cells stably expressing the respective FeLV receptors. 48 hours post-infection, MDTF 2 
cells were stained for β-galactosidase activity as previously described (Kimpton and 3 
Emerman, 1992). 4 
 5 
2.3. Immunoblots for Viral Protein Expression 6 
 7 
Concentrated virus samples were prepared by ultracentrifugation of cell-free tissue 8 
culture fluid from infected cultures. Samples were subjected to sodium dodecyl 9 
sulphate-polyacrylamide gel electrophoresis and immunoblotting using the iBlot 10 
transfer system (InVitrogen). The primary antibodies for FeLV detection were a 1:500 11 
dilution of mouse monoclonal antibody specific for the capsid (p27) protein 12 
(vpg19.1), and a 1:105 dilution of mouse ascites preparation specific against the SU 13 
domain of Env (gp70). 14 
 15 
For the detection of RD114 virus, goat polyclonal antiserum specific for the RD114 16 
capsid protein was used at a 1:5000 dilution. Secondary antibody was anti-mouse 17 
or anti-goat alkaline phosphatase-labelled IgG from horse (Vector Laboratories, 18 
Peterborough, U.K). Proteins were visualised using an alkaline phosphatase 19 
substrate visualisation kit (Vector Laboratories). 20 
 21 
2.4. Cloning of viral RNA and genomic DNA PCR Products  22 
 23 
 9 
Viral RNA was extracted from concentrated viral pellets using an RNA preparation kit 1 
(QIAmp UltraSense Virus Kit, QIAgen). Following DNase treatment of RNA, cDNA was 2 
prepared using oligo-dT primers and a commercial cDNA synthesis kit (Roche 3 
Applied Science, Burgess Hill, U.K). Genomic DNA (gDNA) from infected cell cultures 4 
was isolated using a commercial kit (DNEasy Blood Kit, QIAgen). A high-fidelity DNA 5 
polymerase (Roche) was used to amplify FeLV env and LTR transcripts (primer 6 
details and PCR conditions available upon request). Viral RNA was included in PCRs 7 
to ensure contaminating cellular gDNA was not present. PCR products were 8 
separated by electrophoresis and purified from agarose using a commercial kit 9 
(QIAquick Gel Extraction Kit, QIAgen). Amplicons were TA-cloned into the pCR2.1 10 
vector (InVitrogen) according to standard procedures. Plasmid purification of positive 11 
transformants was conducted with a commercial kit (Plasmid MiniKit, QIAgen). 12 
 13 
Both PCR products and plasmid preparations were sequenced using the BigDye 14 
Terminator v1.1 Kit and analysed using an ABI Prism 3100 Genetic Analyser 15 
(Applied Biosystems, Paisley, U.K) and the computer program DNADynamo (Blue 16 
Tractor Software, North Wales, U.K). The sequences described within this study have 17 
been deposited with GenBank (accession numbers pending).  18 
 19 
3.  RESULTS AND DISCUSSION 20 
 21 
FEA cells were infected with a panel of 300 FeLV field isolates, and interference 22 
assays were used to classify them according to their subgroups. Two isolates, 23 
 10 
designated FeLV-2518 and FeLV-4314, displayed the FeLV-B phenotype alone with 1 
no evidence of FeLV-A co-infection. This initial result was confirmed using MDTF cells 2 
stably transduced to express the various FeLV receptors (feThTr1, hFLVCR1 and 3 
fePit1) (data not shown). Although FeLV-B infection is highly associated with FeLV-4 
induced lymphomas (Sheets et al., 1993; Tsatsanis et al., 1994) and leukemias 5 
(Jarrett et al., 1978; Tzavaras et al., 1990), the clinical history and disease status of 6 
the host is unknown. The disease manifestation of these FeLV isolates is therefore 7 
not known. 8 
 9 
Cell-free filtered supernatant from the infected FEA cells was used to infect 10 
HEK293T cells. Immunoblots of cell-free virions from both FEA and HEK293T cells 11 
were conducted to detect the capsid protein, confirming they were persistently 12 
infected (data not shown). A subsequent receptor usage assay confirmed the 13 
isolates had retained their FeLV-B phenotype following infection of the HEK293T 14 
cells. Immunoblots for detection of gp70 (the surface unit domain of Env) indicated 15 
that both isolates produced a full-length envelope glycoprotein (Figure 1). The Env of 16 
FeLV-2518 appeared to be of a slightly smaller size than that of FeLV-4314. This 17 
may be due to internal deletions within the FeLV-2518 env gene or differences in 18 
the glycosylation patterns of the proteins. 19 
 20 
A PCR was conducted with exogenous FeLV-specific primers, to amplify specifically 21 
exogenous env transcripts from viral cDNA, prepared from RNA isolated from 22 
purified viral particles. Products could not be detected from FeLV-4314 templates; 23 
however FeLV-2518 cDNA produced a ~1kB amplicon (Figure 2). This could be 24 
 11 
reproduced using cellular gDNA from both infected HEK293T and FEA cells (data not 1 
shown), the template of which would be integrated provirus. Cloning and sequence 2 
analysis of the ~1kB amplicon revealed it to be an exogenous FeLV env transcript 3 
with an internal ~900bp deletion, spanning the SU/TM cleavage site, hydrophobic 4 
membrane anchor and the majority of the TM domain. It also contained a premature 5 
termination codon, preventing the final 37 amino acids from being synthesised. This 6 
defective exogenous FeLV genome was termed FeLV-2518(A). If this Env protein was 7 
expressed it would presumably be secreted; however gp70-specific immunoblots did 8 
not indicate it was present in either cell lysates or cell-free supernatant (data not 9 
shown). It is possible that this protein, if expressed, may either prevent FeLV-A 10 
infection through competitive receptor-binding, or enhance infection with other 11 
viruses in a similar manner to that of FeLIX. FeLIX is an endogenously-encoded Env 12 
peptide required for FeLV-T infection of T-lymphocytes, allowing the otherwise FeLV-A 13 
virus to utilise fePit1 for cell entry (Anderson et al., 2000; Lauring et al., 2001). To 14 
date none of our experiments indicate that either of these situations occurs with 15 
FeLV-2518(A) Env proteins. 16 
 17 
To confirm the presence of this exogenous FeLV genome in the virions of FeLV-18 
2518, a PCR to specifically amplify the U3 region of exogenous FeLV LTRs was 19 
conducted upon genomic DNA from both FEA and HEK293T cells. Surprisingly, 20 
amplicons of the expected size (~500bp) were observed from both FeLV-2518 and -21 
4314 templates (data not shown). Sequence analysis confirmed these were 22 
integrated exogenous FeLV U3 motifs. As the sequence of this antisense primer 23 
(termed FeLV U3 Rev Kpn1, sequence available upon request) was conserved 24 
 12 
between published endogenous and exogenous FeLV sequences, it was then used 1 
with a novel sense primer to specifically amplify endogenous FeLV U3 sequences 2 
from gDNA. Amplicons were observed in all templates from FEA cells, as expected, 3 
but not in those of infected HEK293T cells (data not shown), indicating transmission 4 
of an endogenous LTR had not occurred and was therefore not present in either 5 
FeLV-2518 or -4314 virions. 6 
 7 
Although there appeared to be exogenous LTRs present in both virus isolates, the 8 
lack of a full length exogenous env transcript in either case led us to predict an 9 
endogenous virus was contributing to the replication and transmission potential of 10 
both isolates, despite the fact that endogenous U3 sequences could not be detected 11 
in infected HEK293T cells. To ensure the replication-competent endogenous feline 12 
retrovirus RD-114 was not contributing to transmission of these isolates, we 13 
performed both immunoblots against the capsid protein and a PCR to detect RD-14 
114 env transcripts. We did not detect either RD-114 transcripts or proteins (data 15 
not shown). We then conducted a PCR upon gDNA from infected HEK293T cells, 16 
using an enFeLV-env-specific sense primer and the conserved U3 antisense primer. 17 
Amplicons of the expected size, 2.2kB, were observed from both FeLV-2518 and -18 
4314 templates (see Figure 3). Cloning and sequence analysis of these revealed 19 
both products to be recombinant env sequences with an exogenous FeLV LTR. This 20 
correlates with the seemingly-conflicting results produced in other PCR assays. We 21 
surmise that these ostensibly-endogenous FeLV genomes are producing the full-22 
length Env glycoproteins observed in Figure 1. It is not known which of the viral 23 
genomes found within FeLV-2518 virions contributes the remaining viral proteins. 24 
 13 
 1 
The 3’ recombination breakpoint of FeLV-4314 is approximately 200bp downstream 2 
of the SU/TM cleavage site (Figure 4). It consists of a 21bp stretch (encoding the 3 
SISALEK motif within TM), conserved between both the prototype FeLV-A(Glasgow-1) 4 
and enFeLV viral genomes. Upstream there are 12 randomly-distributed mutations, 5 
encoding 7 amino acid substitutions, which distinguish this from the full-length 6 
enFeLV genome AY364318 (Roca et al., 2004). This indicates that although the 7 
contributing enFeLV locus is not definitively known it is likely to be a recently-8 
endogenised retrovirus. We hypothesise that the majority of the TM domain, and the 9 
accompanying U3 region of the 3’ LTR, are derived from an exogenous FeLV-A 10 
genome that is no longer present within the isolate. 11 
 12 
Comparatively, the 3’ recombination breakpoint of the FeLV-2518 genome is an 18 13 
nucleotide stretch encoding the WTSDFC motif, ~200bp upstream of the SU/TM 14 
cleavage site (Figure 4). Within the endogenously-encoded region, there is only one 15 
nucleotide difference (causing a K to I substitution) when compared to the 16 
AY364318 genome. Sequence comparison of FeLV-2518 and FeLV-2518(A) 17 
revealed homologous stretches both within the 3’ region of env and across the U3 18 
region. This provides evidence for FeLV-2518(A) being the source of the exogenous 19 
regions within the functional FeLV-2518 genome. However numerous mutations 20 
were observed clustered within the region immediately downstream of the stop 21 
codon of FeLV-2518(A). As this env is assumed to be defective and not expressed, 22 
this genetic drift may have occurred since the recombination event that formed the 23 
 14 
functional FeLV-2518 viral genome, as there is no longer selective pressure upon 1 
the exogenous genome to retain functionality. 2 
 3 
There are 12 nucleotide differences between the exogenous U3 domains of FeLV-4 
2518 and -4314, making it unlikely that they arose from a conserved parental virus. 5 
Thus a recombination event resulting in a mostly-endogenous viral env gene with 6 
exogenous LTRs appears to have occurred separately on at least two occasions in 7 
naturally infected hosts, and manifests as an FeLV-B infection without a coinfection 8 
of FeLV-A. This is also the first identification of a 3’ recombination breakpoint being 9 
identified within the TM domain of a FeLV-B isolate, as the majority of recombination 10 
sites span a central 250bp region of SU (Sheets et al., 1992). The 5’ recombination 11 
breakpoints of both FeLV-2518 and -4314 are yet to be identified; however we 12 
hypothesise the majority of the viral genomes are of endogenous origin and have 13 
arisen from a recently-endogenised FeLV element. Evidence for this comes from the 14 
fact that both these viral genomes, as well as the full-length enFeLV genomes (Roca 15 
et al., 2004) contain the C11D8 epitope (MGPNL, located in the central region of the 16 
SU domain (Elder et al., 1987; Nunberg et al., 1984)) which is not found in defective 17 
enFeLV elements such as CFE-6 (McDougall et al., 1994; Sheets et al., 1993). This 18 
also provides evidence that, although mostly-endogenously encoded, these Env 19 
glycoproteins may evoke an immune response in their hosts. 20 
 21 
Prior to the discovery of putatively conserved enFeLV genomes, some 5’ 22 
recombination points in FeLV-B genomes were known to be located within the pol 23 
gene indicating it must be functional in some enFeLV loci (Overbaugh et al., 1988; 24 
 15 
Pandey et al., 1991). The few enFeLV-encoded gag genes studied were found to be 1 
highly mutated and thus assumed to be defective; however both the packaging 2 
signal and leader sequences of these are intact (Berry et al., 1988). It is therefore 3 
feasible that expression and packaging of defective RNA transcripts alongside 4 
exogenous genomes may occur even in host cats lacking the full-length enFeLV loci. 5 
Although the co-packaging of two distinct FeLV genomes within one virion has not 6 
been observed directly, co-packaging of both FeLV and MLV RNAs resulting in novel 7 
recombinant genomes has been observed in vitro (Pandey et al., 1991; Yin and Hu, 8 
1997). There is also the notable case of AKR mice, which develop leukemia 9 
following development of a replication-competent virus from recombination events 10 
between three endogenous elements. Interestingly, in this case a specific locus (Bxv-11 
1) contributes the LTRs which directly influence the pathogenic potential of the final 12 
virus (Coffin et al., 1989). 13 
 14 
The 3’ LTR is often a contributing factor in the virulence and oncogenic potential of 15 
retroviruses. Promoter and enhancer-like elements, including the CCAAT (Grosschedl 16 
and Birnstiel, 1980) and Goldberg-Hogness boxes (Corden et al., 1980; Proudfoot, 17 
1979), are located within the U3 region and may activate proto-oncogenes 18 
downstream of the site of insertion (Fan, 1997; Levy et al., 1993). There are 19 
numerous examples of specific FeLV U3 domains, usually containing short repeats 20 
either upstream or within the enhancer regions, being associated with heightened 21 
pathogenesis. These include cases of FeLV-related multicentric lymphoma (Athas et 22 
al., 1995; Chandhasin et al., 2004) and acute myeloid leukemia (Hisasue et al., 23 
2009; Matsumoto et al., 1992; Nishigaki et al., 1997). These repeated motifs are 24 
 16 
not found in the LTRs detailed within this study. The U3 domain of exogenous 1 
gammaretroviral LTRs is also known to activate the AP-1 pathway (Abujamra et al., 2 
2003; Ghosh and Faller, 1999; Weng et al., 1995), which is involved in cancer 3 
progression. Endogenous LTRs do not exert this effect when expressed (Ghosh et al., 4 
2000), therefore the acquisition of exogenous LTRs for a mostly-endogenous FeLV 5 
genome would almost certainly alter its pathogenic potential. 6 
 7 
4.  CONCLUSIONS 8 
 9 
Although we did not identify any instances of enFeLV transmission, which would 10 
have displayed a FeLV-B phenotype by interference and receptor usage assays, we 11 
did identify two FeLV field isolates (FeLV-2518 and -4314) that presented as FeLV-B 12 
alone, without FeLV-A co-infection. These viral genomes are recombinants and it is 13 
suspected that the majority is of endogenous origin. We hypothesise that in the case 14 
of FeLV-4314, the exogenous U3 region allowed the recombinant virus to achieve 15 
higher rates of transcription due to its promoter and enhancer elements, possibly 16 
contributing to it outgrowing the exogenous virus that was originally present. In the 17 
case of FeLV-2518, a defective FeLV-A genome is also packaged and maintained 18 
throughout infection of naïve cells. It is not known which gag-pol genes (either 19 
endogenous or exogenous) contribute to the viral replication of this isolate. Future 20 
work will concentrate on cloning and sequencing the entire viral genome of both 21 
isolates, including the truncated FeLV-2518(A) genome, to identify the 5’ 22 
recombination points. Additionally, studies are underway to determine whether the 23 
 17 
two genomes within FeLV-2518 co-package and dimerise within virions or are 1 
packaged separately. It may also be of interest to determine whether the viruses are 2 
able to utilise the FeLV-B receptor homologue fePit2, as it has been observed that 3 
the degree of viral genome originating from enFeLV correlates to the ability of 4 
isolates to utilise fePit2 (Boomer et al., 1997; Sugai et al., 2001). 5 
 6 
To the best of our knowledge, this is the first isolation of FeLV viruses displaying the 7 
B subgroup phenotype without the presence of a fully functional helper FeLV-A virus. 8 
These results may shed some light upon the biology of FeLV-B formation. Since both 9 
of these ostensibly subgroup B viruses occurred naturally, it is likely that enFeLV 10 
expression contributes to FeLV pathogenesis more than was assumed previously. 11 
 12 
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Figure 1: Immunoblot against the gp70 (SU) domain of Env. Samples were 1 
concentrated viral particles, prepared as described in text. 2 
3 
 28 
Figure 2: PCR products from viral cDNA. Primers specifically amplified the env genes 1 
of exogenous FeLV transcripts. 2 
3 
 29 
Figure 3: PCR products from gDNA templates. Sense primer was specific to the 5’ 1 
region of endogenous FeLV env, antisense primer was based upon a portion of the 2 
U3 motif conserved between enFeLV and exogenous FeLV. 3 
4 
 30 
Figure 4: (a) Partial Env protein alignment of FeLV-2518, -4314 and prototype FeLV-1 
A (Glasgow-1) sequences. Boxed regions indicate predicted 3’ recombination 2 
breakpoints for the isolates described in this study. Vertical line denotes the SU/TM 3 
cleavage site.  (b) Schematic of the env and LTR genomic regions described within 4 
this study. 5 
